コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 1 indicates a fatty breast and 4 indicates a dense breast).
2 neously dense breasts (24% of all women with dense breasts).
3 tremely dense breasts (21% of all women with dense breasts).
4 s of age or women > or =50 years of age with dense breasts).
5 upplemental screening options for women with dense breasts.
6 om 100% in fatty breasts to 45% in extremely dense breasts.
7 is independently higher in older women with dense breasts.
8 a woman with fatty breasts and a woman with dense breasts.
9 and lower in stage than palpable cancers in dense breasts.
10 n, especially in women with radiographically dense breasts.
11 hesis and ultrasound in mammography-negative dense breasts.
12 p to 14% in the classification of women with dense breasts.
13 women with mammography-negative screens and dense breasts.
14 t increased risk, particularly in those with dense breasts.
15 ual screening, younger women, and women with dense breasts.
16 en of 14 cancers were detected in women with dense breasts.
17 programs, particularly in younger women with dense breasts.
18 calculated for younger women and those with dense breasts.
19 gital mammography is standard for women with dense breasts.
20 riate in the much larger group of women with dense breasts.
21 l, 36.9% of mammograms were rated as showing dense breasts.
22 r those younger than 50 years and those with dense breasts.
23 digital mammography and to the prevalence of dense breasts.
24 mutation carriers who have mammographically dense breasts.
25 breast cancer in women with radiographically dense breasts.
26 that 20 of the 45 women had heterogeneously dense breasts, 1 had extremely dense breasts, 20 had pri
27 tly suggested reasons for possible miss were dense breasts (12 of 35; 34%) and distracting lesions (3
29 terogeneously dense breasts, 1 had extremely dense breasts, 20 had primarily fatty breasts, and 4 had
31 risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts).
32 s; interquartile range, 44 to 78 years) with dense breasts, 24 additional BCs were detected (23 invas
33 vs. 75.6%; P = 0.071), those with extremely dense breasts (83.6% vs. 68.1%; P = 0.051), and pre- or
34 tal ultrasonography screening for women with dense breasts after a negative screening mammography res
36 66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, wi
38 study population comprised 37 patients with dense breasts and a family or personal history of breast
41 o 49 years are more likely to have extremely dense breasts and estrogen receptor-negative tumors; if
42 ost markedly reduced with the combination of dense breasts and estrogen replacement therapy use; ther
44 r patients with extremely or heterogeneously dense breasts and for patients in their 5th and 7th deca
45 ndular, heterogeneously dense, and extremely dense breasts and for patients younger than 40 years, th
46 ng mammography facilities to tell women with dense breasts and negative results on screening mammogra
47 prospectively examined, all 3,626 women with dense breasts and normal mammographic and physical exami
48 equiring that women be notified if they have dense breasts and that they be advised to discuss supple
49 nsitivity of 2D mammography in patients with dense breasts and the specificity of 2D mammography for
50 ty breasts vs 85.4% for those with primarily dense breasts) and was lower among those with a family h
51 age of 50 years, women with radiographically dense breasts, and premenopausal or perimenopausal women
52 nd for women aged 40 to 49 years, those with dense breasts, and those using combination hormone thera
55 nopausal women younger than 50 years who had dense breasts at film mammography comprised the only sub
56 m high-grade) with heterogeneously or highly dense breasts at mammography and one papillary low/inter
57 liant retrospective review of 935 women with dense breasts at mammography who subsequently underwent
58 o 74 years with heterogeneously or extremely dense breasts averted 0.36 additional breast cancer deat
59 imenopausal women younger than 50 years with dense breasts, but film tended nonsignificantly to perfo
60 t breast cancer (BC) in mammography-negative dense breasts, but these modalities have not been direct
61 detection of node-negative breast cancer in dense breasts by 7.5 per 1000 women screened (95% CI: 3.
62 ered to women in the general population with dense breasts can aid detection of small mammographicall
63 Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone
65 sult (range, 345 to 421) per 1000 women with dense breasts compared with biennial screening by mammog
67 en at 21 sites with elevated cancer risk and dense breasts consented to 3 annual independent screens
68 for breast cancer screening in patients with dense breast, conventional anatomical ultrasound lacks s
69 aphy screening for only women with extremely dense breasts cost $246,000 per QALY gained (range, $74,
70 with screen-film mammography, in women with dense breasts demonstrated in the DMIST was most likely
73 alone among U.S. women aged 50-74 years with dense breasts from a federal payer perspective and a lif
74 In contrast, interval breast cancers in dense breasts (> 40.9% mammographic density) were less a
77 Debate on adjunct screening in women with dense breasts has followed legislation requiring that wo
80 aphy in a generalizable cohort of women with dense breasts increased the cancer detection yield of cl
81 ltrasound in Women With Mammography-Negative Dense Breasts' interim analysis shows that ultrasound ha
82 ltrasound in Women With Mammography-Negative Dense Breasts is a prospective multicenter study recruit
83 reening for U.S. women aged 50-74 years with dense breasts is likely to be cost-effective if priced a
84 n selected populations, including women with dense breasts, mammographically indeterminate lesions >1
85 hose with heterogeneously dense or extremely dense breasts (n = 427), normal or benign ultrasounds.
86 or other methods in women identified to have dense breasts on an otherwise negative screening mammogr
87 omen with heterogeneously dense or extremely dense breasts on mammography (difference, 0.11; 95 perce
89 = 1007) who had heterogeneously or extremely dense breasts on prior mammograms and additional risk fa
90 -year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and het
91 01) but no difference in the percentage with dense breasts or in the percentage with availability of
95 e densest breasts) and in younger women with dense breasts (P =.02); the effects were independent.
97 malignancy in 18 of 20 (90%) cancers despite dense breast parenchymal patterns (BI-RADS types 3 and 4
98 h Volpara classifying 51% of women as having dense breasts, Quantra classifying 37%, and clinical BI-
99 all women with heterogeneously or extremely dense breasts shifted to scattered fibroglandular breast
101 s--were significantly greater for women with dense breasts than for women with nondense breasts, even
103 re common in mammograms with heterogeneously dense breast tissue (8% unacceptable) than in those with
104 among the 156 women who had radiographically dense breast tissue (Breast Imaging Reporting and Data S
105 percentage of mammograms reported as showing dense breast tissue (hereafter called "dense mammograms"
107 examination for the subset of women who have dense breast tissue and are at high risk of breast cance
108 cent mammographic density, the proportion of dense breast tissue area to total breast area, declines
109 ature were used to recommend that women with dense breast tissue at screening mammography follow supp
110 r for the most dense compared with the least dense breast tissue categories ranges from 1.8 to 6.0, w
113 6, 2809 women, with at least heterogeneously dense breast tissue in at least 1 quadrant, were recruit
115 ften develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mam
116 of women with heterogeneously and extremely dense breast tissue, a working group of breast imagers a
117 of BRCA1 and BRCA2 mutations tended to have dense breast tissue, and their mammographic patterns ten
118 ancer detection, especially in patients with dense breast tissue, but its utility is limited by low d
119 n particular, issues of risk associated with dense breast tissue, masking of cancers by dense tissue
121 ty ranged from 62.9% in women with extremely dense breasts to 87.0% in women with almost entirely fat
122 increased from 89.1% in women with extremely dense breasts to 96.9% in women with almost entirely fat
123 The likelihood of a woman being told she has dense breasts varies substantially according to which ra
124 ncer associations; odds ratios for extremely dense breasts versus scattered fibroglandular densities
125 However, the highest peak SUV observed in dense breasts was 1.39, which is well below the SUV of 2
126 tives with breast cancer, or heterogeneously dense breasts were associated with a 1.5- to 2.0-fold in
127 eterogeneously (50%-75%) or extremely (>75%) dense breasts were included, regardless of further risk
129 erties for scintimammography of fatty versus dense breasts were, respectively, sensitivity, 72% versu
130 f 1 for screening of asymptomatic women with dense breasts who are 40 years old and older, it does no
131 one, and mammography plus BSGI in women with dense breasts who were asymptomatic and examined in the
132 er sensitivity and specificity in women with dense breasts, who experience higher breast cancer risk.
133 ously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.6
134 tal ultrasonography screening for women with dense breasts would substantially increase costs while p
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。